• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The 2011 EBCTCG polychemotherapy overview.

作者信息

Palmieri Carlo, Jones Alison

机构信息

Division of Cancer, Imperial College London, London W12 0NN, UK.

出版信息

Lancet. 2012 Feb 4;379(9814):390-2. doi: 10.1016/S0140-6736(11)61823-0. Epub 2011 Dec 5.

DOI:10.1016/S0140-6736(11)61823-0
PMID:22152852
Abstract
摘要

相似文献

1
The 2011 EBCTCG polychemotherapy overview.2011年早期乳腺癌协作组多药化疗综述。
Lancet. 2012 Feb 4;379(9814):390-2. doi: 10.1016/S0140-6736(11)61823-0. Epub 2011 Dec 5.
2
An interpretation of the EBCTCG data.
Oncologist. 2007 May;12(5):505-9. doi: 10.1634/theoncologist.12-5-505.
3
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.早期乳腺癌的多药化疗：随机试验综述。早期乳腺癌试验者协作组
Lancet. 1998 Sep 19;352(9132):930-42.
4
Polychemotherapy for early breast cancer.
Lancet. 2001;358(9299):2170. doi: 10.1016/S0140-6736(01)07203-8.
5
Polychemotherapy for early breast cancer.
Lancet. 1998 Nov 7;352(9139):1554. doi: 10.1016/S0140-6736(05)60364-9.
6
[Polychemotherapy versus monotherapy in metastatic breast carcinoma].
Strahlenther Onkol. 1999 Sep;175(9):471.
7
Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized Trial.关于：早期乳腺癌的多药化疗：国际辅助性乳腺癌化疗随机试验的结果
J Natl Cancer Inst. 2007 Sep 19;99(18):1416. doi: 10.1093/jnci/djm109. Epub 2007 Sep 11.
8
[Effectiveness of mammary scintigraphy for determining the results of neoadjuvant polychemotherapy in breast cancer].
Vopr Onkol. 2013;59(3):328-33.
9
[Treatment of advanced cancer of the breast with FEC polychemotherapy using epirubicin at 75 mg/m2 dose (FEC 75)].
Bull Cancer. 1990;77(10):1033-5.
10
[Combination of aminoglutethimide and polychemotherapy for the treatment of predominant bone metastasis in breast cancer].氨鲁米特与联合化疗联合治疗乳腺癌主要骨转移
Dtsch Med Wochenschr. 1986 Nov 7;111(45):1726-9. doi: 10.1055/s-2008-1068700.

引用本文的文献

1
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.ESMO-Magnitude of Clinical Benefit Scale（V.1.1）在早期乳腺癌治疗领域的应用。
ESMO Open. 2020 Sep;5(5):e000743. doi: 10.1136/esmoopen-2020-000743.
2
Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients.激素受体阳性和淋巴结阳性的早期乳腺癌患者接受符合指南的化疗可改善总生存和无转移生存，而老年患者的获益有限。
Arch Gynecol Obstet. 2020 Feb;301(2):573-583. doi: 10.1007/s00404-019-05387-3. Epub 2019 Nov 20.
3
Individualized Treatment Analysis Of Breast Cancer With Chronic Renal Failure.
慢性肾衰竭乳腺癌的个体化治疗分析
Onco Targets Ther. 2019 Sep 20;12:7767-7772. doi: 10.2147/OTT.S223729. eCollection 2019.
4
Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer.雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌中肿瘤浸润淋巴细胞的临床病理因素与临床结局之间的关联。
Oncol Lett. 2019 Feb;17(2):2177-2186. doi: 10.3892/ol.2018.9853. Epub 2018 Dec 19.
5
ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells.ADAM12-L 赋予乳腺癌细胞获得性氟尿嘧啶耐药性。
Sci Rep. 2017 Aug 29;7(1):9687. doi: 10.1038/s41598-017-10468-x.
6
Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌病例中，癌干细胞标志物醛脱氢酶1在早期、晚期和无复发情况下的表达差异。
Breast Cancer Res. 2016 Jul 2;18(1):73. doi: 10.1186/s13058-016-0731-3.
7
Adjuvant Therapy Reduces Rate of Dissemination but Shortens Survival Thereafter.辅助治疗降低了播散率，但随后缩短了生存期。
Oncologist. 2015 Jul;20(7):e23. doi: 10.1634/theoncologist.2015-0116. Epub 2015 Jun 11.
8
In reply.作为答复。
Oncologist. 2015 Jan;20(1):88. doi: 10.1634/theoncologist.2014-0284.
9
Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.早期乳腺癌的当前治疗方法：辅助治疗和新辅助治疗。
F1000Res. 2014 Aug 19;3:198. doi: 10.12688/f1000research.4340.1. eCollection 2014.
10
PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs.PTK7 作为乳腺癌患者对辅助化疗反应和蒽环类药物耐药的潜在预后和预测标志物。
Onco Targets Ther. 2014 Oct 6;7:1723-31. doi: 10.2147/OTT.S62676. eCollection 2014.